{Reference Type}: Multicenter Study
{Title}: Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study).
{Author}: Måseide RJ;Berntorp E;Astermark J;Olsson A;Bruzelius M;Frisk T;Nummi V;Lassila R;Tjønnfjord GE;Holme PA;
{Journal}: Haemophilia
{Volume}: 30
{Issue}: 1
{Year}: 2024 Jan 20
{Factor}: 4.263
{DOI}: 10.1111/hae.14899
{Abstract}: <B>BACKGROUND: </B>The impact of moderate haemophilia on health-related quality of life (HRQoL) and physical activity (PA) is not well known. In previous studies, persons with factor VIII/factor IX activity (FVIII/FIX:C) below 3 IU/dL were associated with a more severe bleeding phenotype than predicted.<BR><B>OBJECTIVE: </B>To explore HRQoL and PA in patients with moderate haemophilia A (MHA) and B (MHB).<BR><B>METHODS: </B>A cross-sectional, multicentre study covering patients with MHA and MHB in Sweden, Finland, and Norway. HRQoL was assessed with the EuroQoL 5-Dimensions (EQ-5D) form and PA with the International Physical Activity Questionnaire among participants aged ≥15 years.<BR><B>RESULTS: </B>We report on 104 patients aged 15-84 years from the MoHem study. Overall, EQ-5D utility was .85 (median) (Q1-Q3 0.73-1.0) with corresponding visual analogue scale (VAS) 80 (70-90), which were similar regardless of treatment modality, FVIII/FIX:C, and MHA or MHB. Pain and mobility were most frequently affected dimensions. Utility (r = -.54), VAS (r = -.42), and PA (r = -.32) correlated negatively with arthropathy (HJHS). Only patients aged 41-50 years displayed lower utility (p = .02) and VAS (p < .01) than the Norwegian population norm. Patients on prophylaxis aged 35-54 years reported higher PA than those treated on-demand (p = .01).<BR><B>CONCLUSIONS: </B>Haemophilic arthropathy had negative impact on HRQoL and PA in Nordic patients with moderate haemophilia. Middle-aged patients captured lower utility and VAS than observed in the general population. Tailored prophylaxis and improved joint health may influence positively on HRQoL and PA also in moderate haemophilia.